Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 18Active not recruiting 7Recruiting 4Withdrawn 3Terminated 3Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 49NIH 4INDUSTRY 4NETWORK 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Plasma cell 1

Conditions

Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 15Paclitaxel 14Taxes 10Cyclophosphamide 9Carboplatin 9Gemcitabine 7Platinum 61,2-diaminocyclohexaneplatinum II citrate 6Trastuzumab 5Radiotherapy 5Oxaliplatin 5Doxorubicin 5Docetaxel 5Cytarabine 5Capecitabine 5Brachytherapy 5fludarabine 4Rituximab 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Fluorouracil 4Dexamethasone 4Watchful Waiting 3Radiotherapy, Conformal 3Pemetrexed 3Nimorazole 3Lenalidomide 3Imatinib Mesylate 3Idarubicin 3Gene Expression Profiling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × NETWORK × Bortezomib × Clear all
NCT06189833 2024-04-23

TAURUS

European Myeloma Network B.V.

Phase 2 Unknown
200 enrolled
Plasma cell

Multiple Myeloma

NCT00516100 2010-01-15

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Aptium Oncology Research Network

Phase 1/2 Unknown
62 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡